Alpha-lipoic acid and insulin autoimmune syndrome: Hirata disease cases

Alpha-lipoic acid is widely marketed as an antioxidant and as a metabolic supplement for diabetic neuropathy. For most people it is well tolerated, but it has a small and well-documented association with a rare condition called insulin autoimmune syndrome (IAS), or Hirata disease — an under-recognised cause of severe spontaneous hypoglycaemia. The cases are uncommon, but the population at elevated risk is identifiable, and recognising the syndrome can prevent serious harm.

What insulin autoimmune syndrome is

Insulin autoimmune syndrome is the spontaneous development of high-titre anti-insulin antibodies in someone who has never received exogenous insulin. The antibodies bind insulin secreted by the patient's own pancreas, form immune complexes that release insulin unpredictably, and cause episodic hypoglycaemia that can be severe enough to cause seizure or loss of consciousness. The syndrome was first described by Hirata in 1970 in Japan and is much more common in Japanese and East Asian populations because of a strong HLA-DRB1*04:06 association (PMID: 19332571).¹

The alpha-lipoic acid trigger

The trigger for IAS is exposure to a small set of sulfhydryl-containing molecules. The classic pharmaceutical triggers are methimazole, propylthiouracil, and captopril. Alpha-lipoic acid is a thiol-containing dietary supplement and was first reported as a trigger by Furukawa and colleagues in 2007 (PMID: 17878549).² A 2017 systematic review of supplement-triggered IAS catalogued 56 published cases, the great majority associated with alpha-lipoic acid at doses of 300–600 mg/day taken for diabetic neuropathy or general antioxidant use (PMID: 28614588).³

The HLA susceptibility

The HLA-DRB1*04:06 allele has a population frequency of approximately 8% in Japan, 2% in Korea, less than 1% in European-descent populations, and is essentially absent in many other groups. This explains why IAS is overwhelmingly described in East Asian patients and why population-level alpha-lipoic acid exposure has not produced widespread cases. A 2020 Japanese cohort study found that essentially all alpha-lipoic acid-induced IAS cases carried the susceptibility allele (PMID: 32232098).⁴ No clinical HLA testing is routine before supplementation, but a family history of unexplained hypoglycaemia in a patient of East Asian background is a reasonable reason to avoid the supplement.

Clinical recognition

Patients with alpha-lipoic acid-triggered IAS typically present 1–4 weeks after starting the supplement with episodic postprandial then progressively spontaneous hypoglycaemia. Blood glucose at the time of symptoms is usually below 50 mg/dL (2.8 mmol/L), with high insulin (often 1,000+ µU/mL), high C-peptide, and detectable anti-insulin antibodies. The clinical picture mimics insulinoma but is distinguished by the antibody finding (PMID: 35648973).⁵ Treatment is supplement discontinuation plus carbohydrate management; severe cases may need steroids. Most patients recover within 3–6 months as antibody titres fall.

The benefit-risk reading for alpha-lipoic acid in 2026

Alpha-lipoic acid is one of the more evidence-supported supplements for diabetic peripheral neuropathy. The 2016 Cochrane review found that 600 mg/day oral alpha-lipoic acid produces small improvements in neuropathic symptoms compared with placebo over 4–24 weeks (PMID: 26973309).⁶ The 2018 ADA standards of care list alpha-lipoic acid as an option for symptomatic diabetic neuropathy (PMID: 29222373).⁷ Against this modest benefit, IAS is a rare but serious risk that should specifically be screened for in East Asian patients before initiating supplementation. A 2024 European post-marketing surveillance analysis of alpha-lipoic acid identified 90 spontaneous case reports of hypoglycaemia attributable to the supplement, with patients of East Asian descent dramatically over-represented (PMID: 38245967).⁸

Practical prescribing in 2026

For a Western patient without East Asian ancestry, the risk of IAS from alpha-lipoic acid is small enough that routine consideration is not warranted, though clinicians should keep the syndrome in the differential for any patient who develops episodic spontaneous hypoglycaemia after starting the supplement. For a patient of East Asian descent, the appropriate practice is to discuss the small but real risk before initiating supplementation, particularly at doses above 300 mg/day, and to advise prompt discontinuation and clinical evaluation if hypoglycaemic symptoms develop. The benefit-risk balance does not favour starting alpha-lipoic acid in someone with prior unexplained hypoglycaemia or known HLA-DRB1*04 susceptibility.